An explosive report has painted a new, troubling picture of Elon Musk as an alleged drug user, a claim that has added another layer to the already complex public persona of the tech titan known for his erratic behavior and outlandish statements. Despite Musk's past justifications for his erratic behavior and "nonsense" speech, including claims of fatigue, depression, and overwork, The Wall Street Journal's latest revelation suggests that Musk's long-term drug use might be a contributing factor. Musk's lawyer has denied these allegations.

The report cited instances of Musk's public consumption of marijuana in 2018 and his use of ketamine to treat depression, with Musk himself touting the benefits of ketamine in a tweet.

The Wall Street Journal highlighted that executives at Tesla and SpaceX are deeply concerned about how Musk's alleged drug use could affect the management of his six companies and billions of dollars in contracts. Musk's unpredictable behavior and incoherent speech have been noted for years, with incidents like his infamous "funding secured" tweet about taking Tesla private and his public marijuana consumption costing Tesla billions in market value and drawing scrutiny from NASA.

According to insiders, Musk's drug use includes substances like psychedelics, cocaine, ecstasy, and magic mushrooms at private parties around the world. The report also suggests that Musk's mental health explanations, such as depression and Asperger's syndrome, may be overshadowed by the alleged drug addiction.

The repercussions of these allegations could be significant for Musk's vast business empire, which includes Tesla, SpaceX, social media platform X, The Boring Co., Neuralink, and an AI company, xAI. The intertwined nature of his companies increases the risk of conflicts of interest and could endanger approximately $1 trillion in assets, thousands of jobs, and parts of the U.S. space program.

Tesla's board and executives point to drug use as another potential reason for Musk's erratic behavior, and the report details various instances where Musk allegedly consumed drugs. Despite these allegations, Musk's lawyer insists that Musk regularly passes random drug tests at SpaceX.

The concern among executives is not just about Musk's health but the impact his behavior may have on the companies he oversees and their lucrative contracts. Former Tesla director Linda Johnson Rice reportedly expressed concerns about Musk's erratic behavior, leading her to not seek reelection to the board in 2019.

Musk's public antics have already cost him and his companies dearly, with significant fines from the SEC, a drop in Tesla's market value, and additional scrutiny and compliance costs from NASA. As Musk controls a tightly connected empire of six companies, the stakes are high, and the potential fallout from these allegations could have far-reaching consequences for his business ventures, employees, and investors.